MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study evaluating zandelisib in patients with relapsed or refractory follicular lymphoma. The webcast will also review the zandelisib program and provide a corporate update.

A live audio webcast of the event will be available on the Investors section of MEI’s website at https://www.meipharma.com/investors/events-calendar. A replay of the webcast will be archived on MEI’s website for 30 days following the event.